AGRX vs. SXTP, VRPX, ONCO, NTBL, BPTSY, MBIO, SNOA, SLRX, BPTS, and CYTO
Should you be buying Agile Therapeutics stock or one of its competitors? The main competitors of Agile Therapeutics include 60 Degrees Pharmaceuticals (SXTP), Virpax Pharmaceuticals (VRPX), Onconetix (ONCO), Notable Labs (NTBL), Biophytis (BPTSY), Mustang Bio (MBIO), Sonoma Pharmaceuticals (SNOA), Salarius Pharmaceuticals (SLRX), Biophytis (BPTS), and Altamira Therapeutics (CYTO). These companies are all part of the "pharmaceutical preparations" industry.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Agile Therapeutics (NASDAQ:AGRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, community ranking, analyst recommendations, profitability and dividends.
60 Degrees Pharmaceuticals has higher earnings, but lower revenue than Agile Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Agile Therapeutics, indicating that it is currently the more affordable of the two stocks.
60 Degrees Pharmaceuticals currently has a consensus target price of $2.40, indicating a potential upside of 967.14%. Agile Therapeutics has a consensus target price of $8.50, indicating a potential upside of 2,150.46%. Given 60 Degrees Pharmaceuticals' higher possible upside, analysts plainly believe Agile Therapeutics is more favorable than 60 Degrees Pharmaceuticals.
In the previous week, Agile Therapeutics had 4 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 8 mentions for Agile Therapeutics and 4 mentions for 60 Degrees Pharmaceuticals. Agile Therapeutics' average media sentiment score of 1.78 beat 60 Degrees Pharmaceuticals' score of 0.38 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.
Agile Therapeutics received 423 more outperform votes than 60 Degrees Pharmaceuticals when rated by MarketBeat users. Likewise, 67.41% of users gave Agile Therapeutics an outperform vote while only 33.33% of users gave 60 Degrees Pharmaceuticals an outperform vote.
60 Degrees Pharmaceuticals has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -36.24%.
8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 10.9% of Agile Therapeutics shares are held by institutional investors. 0.5% of Agile Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Agile Therapeutics beats 60 Degrees Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Agile Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agile Therapeutics Competitors List
Related Companies and Tools
